High-Throughput Screening (HTS) Market by Instruments (Liquid Handling, Detection, Imaging), Consumables (Reagents, Kits), Software, Services, Technology (Cell-based, High-content, Label-free), Workflow, Application, Competition - Global Forecast to 2031
The high-throughput screening (HTS) market is expected to reach USD 45.90 billion in 2031 from USD 27.66 billion in 2026, growing at a CAGR of 10.7% during the forecast period. Factors such as the rising adoption of open innovation models, increasing government funding and venture capital investments, and higher R&D spending by pharmaceutical and biotechnology companies. Technological advancements in automation, high-content screening, cell-based assays, label-free detection, and AI-enabled data analysis are further improving screening efficiency and supporting wider adoption of HTS platforms across drug discovery workflows.
By offering, the products segment accounted for the largest share of the high-throughput screening (HTS) market in 2025.
Based on offering, the high-throughput screening (HTS) market is segmented into products and services. In 2025, the products segment held the largest share of the high-throughput screening (HTS) market. This is driven by recurring demand for assay kits, reagents, consumables, microplates, compound libraries, instruments, software, and automation platforms. The segment remains dominant because HTS workflows require continuous use of consumables and integrated instruments throughout assay development, screening, data analysis, and hit confirmation. Strong adoption of automated liquid handlers, microplate readers, high-content imaging systems, and assay-ready kits further supports the revenue contribution of products in the HTS market.
By application, the drug discovery & development segment accounted for the largest share of the high-throughput screening (HTS) market in 2025.
By application, the high-throughput screening (HTS) market is divided into drug discovery & development, basic research & functional genomics, toxicology & safety screening, precision medicine & biomarker discovery, stem cell & regenerative medicine research, and other applications. In 2025, the drug discovery & development segment held the largest share of the high-throughput screening (HTS) market, as HTS is widely used to screen large compound libraries, identify hits, validate targets, and support lead optimization. Pharmaceutical and biotechnology companies continue to rely on HTS platforms to improve early-stage discovery productivity and reduce the time required to move candidates into preclinical development. The segment also benefits from the growing use of phenotypic screening, cell-based assays, 3D models, and high-content imaging to identify more biologically relevant drug candidates.
The Asia Pacific region is expected to grow at the highest CAGR in the high-throughput screening (HTS) market from 2026 to 2031.
The high-throughput screening (HTS) market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by expanding pharmaceutical and biotechnology R&D activity, growing CRO presence, and increasing investments in drug discovery infrastructure. Countries such as China, India, Japan, and South Korea are strengthening their screening capabilities through rising research funding, outsourcing demand, and the adoption of automated laboratory technologies. The region is also benefiting from cost-efficient research operations, expanding biotech start-up activity, and increasing partnerships between global pharma companies and local discovery service providers.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage
This research report categorizes the high-throughput screening (HTS) market by offering (products and services), products by type (instruments; reagents, kits, and consumables; software & informatics; and services), products by technology (biochemical screening technologies, cell-based screening technologies, high-content screening (HCS) technologies, label-free screening technologies, microfluidic & miniaturized screening technologies, 3D cell culture & advanced cellular model technologies, ultra-high-throughput & automation technologies, and AI-enabled & computational screening technologies), products by workflow (assay development & optimization, compound library preparation, high-throughput screening, data analysis & hit identification, hit confirmation, hit validation & characterization), products by end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and other end users), services by type (assay development & optimization services, compound library management services, primary screening services, secondary screening & hit confirmation services, hit validation & characterization services, data analysis & informatics services, and other services), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), application (drug discovery & development, basic research & functional genomics, toxicology & safety screening, precision medicine & biomarker discovery, stem cell & regenerative medicine research, and other applications), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the high-throughput screening (HTS) market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product/service portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the high-throughput screening (HTS) market. This report includes a competitive analysis of top players and upcoming startups in the high-throughput screening (HTS) market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the high-throughput screening (HTS) market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (growing adoption of open innovative models, growing R&D funding and increasing public & private investments, growing adoption of lab automation and robotic screening platforms, and increasing outsourcing of screening activities to CROs and HTS service providers), restraints (high costs associated with HTS instruments and complexity in assay development and validation), opportunities (increasing adoption of HTS technologies in emerging markets and growing application of HTS in drug repurposing and personalized medicine), and challenges (complexity in data management & analysis, standardization challenges in 3D, organoid, and image-based assays)
The report also helps stakeholders understand trends in the high-throughput screening (HTS) market and provides information on key drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their strategies, product/service launches, acquisitions, partnerships, collaborations, recent activities, investments, funding, brand and product comparisons, vendor evaluations, and financial metrics of the HTS sector market.
By offering, the products segment accounted for the largest share of the high-throughput screening (HTS) market in 2025.
Based on offering, the high-throughput screening (HTS) market is segmented into products and services. In 2025, the products segment held the largest share of the high-throughput screening (HTS) market. This is driven by recurring demand for assay kits, reagents, consumables, microplates, compound libraries, instruments, software, and automation platforms. The segment remains dominant because HTS workflows require continuous use of consumables and integrated instruments throughout assay development, screening, data analysis, and hit confirmation. Strong adoption of automated liquid handlers, microplate readers, high-content imaging systems, and assay-ready kits further supports the revenue contribution of products in the HTS market.
By application, the drug discovery & development segment accounted for the largest share of the high-throughput screening (HTS) market in 2025.
By application, the high-throughput screening (HTS) market is divided into drug discovery & development, basic research & functional genomics, toxicology & safety screening, precision medicine & biomarker discovery, stem cell & regenerative medicine research, and other applications. In 2025, the drug discovery & development segment held the largest share of the high-throughput screening (HTS) market, as HTS is widely used to screen large compound libraries, identify hits, validate targets, and support lead optimization. Pharmaceutical and biotechnology companies continue to rely on HTS platforms to improve early-stage discovery productivity and reduce the time required to move candidates into preclinical development. The segment also benefits from the growing use of phenotypic screening, cell-based assays, 3D models, and high-content imaging to identify more biologically relevant drug candidates.
The Asia Pacific region is expected to grow at the highest CAGR in the high-throughput screening (HTS) market from 2026 to 2031.
The high-throughput screening (HTS) market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by expanding pharmaceutical and biotechnology R&D activity, growing CRO presence, and increasing investments in drug discovery infrastructure. Countries such as China, India, Japan, and South Korea are strengthening their screening capabilities through rising research funding, outsourcing demand, and the adoption of automated laboratory technologies. The region is also benefiting from cost-efficient research operations, expanding biotech start-up activity, and increasing partnerships between global pharma companies and local discovery service providers.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (80%) and Demand Side (20%)
- By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), the Middle East & Africa (5%)
Research Coverage
This research report categorizes the high-throughput screening (HTS) market by offering (products and services), products by type (instruments; reagents, kits, and consumables; software & informatics; and services), products by technology (biochemical screening technologies, cell-based screening technologies, high-content screening (HCS) technologies, label-free screening technologies, microfluidic & miniaturized screening technologies, 3D cell culture & advanced cellular model technologies, ultra-high-throughput & automation technologies, and AI-enabled & computational screening technologies), products by workflow (assay development & optimization, compound library preparation, high-throughput screening, data analysis & hit identification, hit confirmation, hit validation & characterization), products by end user (pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and other end users), services by type (assay development & optimization services, compound library management services, primary screening services, secondary screening & hit confirmation services, hit validation & characterization services, data analysis & informatics services, and other services), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), application (drug discovery & development, basic research & functional genomics, toxicology & safety screening, precision medicine & biomarker discovery, stem cell & regenerative medicine research, and other applications), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the high-throughput screening (HTS) market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product/service portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the high-throughput screening (HTS) market. This report includes a competitive analysis of top players and upcoming startups in the high-throughput screening (HTS) market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the high-throughput screening (HTS) market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (growing adoption of open innovative models, growing R&D funding and increasing public & private investments, growing adoption of lab automation and robotic screening platforms, and increasing outsourcing of screening activities to CROs and HTS service providers), restraints (high costs associated with HTS instruments and complexity in assay development and validation), opportunities (increasing adoption of HTS technologies in emerging markets and growing application of HTS in drug repurposing and personalized medicine), and challenges (complexity in data management & analysis, standardization challenges in 3D, organoid, and image-based assays)
- Product/Service Development/Innovation: Detailed insights on newly launched products/services, and technological assessment of the high-throughput screening (HTS) market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the high-throughput screening (HTS) market across varied regions.
- Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the high-throughput screening (HTS) market
The report also helps stakeholders understand trends in the high-throughput screening (HTS) market and provides information on key drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their strategies, product/service launches, acquisitions, partnerships, collaborations, recent activities, investments, funding, brand and product comparisons, vendor evaluations, and financial metrics of the HTS sector market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN HIGH-THROUGHPUT SCREENING MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 HIGH-THROUGHPUT SCREENING MARKET OVERVIEW
3.2 NORTH AMERICA: HIGH-THROUGHPUT SCREENING MARKET, BY PRODUCT TYPE AND COUNTRY
3.3 HIGH-THROUGHPUT SCREENING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET SHARE, BY END USER, 2026 VS 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing adoption of open innovative models
4.2.1.2 Technological advancements
4.2.1.3 Growing R&D funding and increasing public & private investments
4.2.1.4 Growing adoption of lab automation & robotic screening platforms
4.2.1.5 Increasing outsourcing of screening activities to CROs & CDMOs
4.2.2 RESTRAINTS
4.2.2.1 High costs associated with HTS instruments
4.2.2.2 Complexity in assay development and validation
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing adoption of HTS technologies in emerging markets
4.2.3.2 Growing application of HTS in drug repurposing and personalized medicine
4.2.3.3 Expansion of CRISPR, RNAi, and functional genomics screening
4.2.4 CHALLENGES
4.2.4.1 Complexity in data management and analysis
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 INTENSITY OF COMPETITIVE RIVALRY
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 THREAT OF NEW ENTRANTS
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL HIGH-THROUGHPUT SCREENING INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY KEY PLAYER, 2023–2025
5.5.2 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY REGION, 2023–2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT SCENARIO (HS CODE 902730 & 902781)
5.6.2 EXPORT SCENARIO (HS CODE 902730& 902781)
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING SCENARIO
5.10 IMPACT OF 2025 US TARIFFS ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRIES/REGIONS
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia Pacific
5.10.5 IMPACT ON END-USE INDUSTRIES
5.10.5.1 Pharmaceutical & biotechnology companies
5.10.5.2 CROs & CDMOs
5.10.5.3 Academic & research institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS
6.1 TECHNOLOGICAL ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 High-content screening
6.1.1.2 Label-free detection
6.1.1.3 Microfluidics
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Laboratory automation & robotic integration
6.1.2.2 Mass spectrometry
6.1.2.3 Flow cytometry
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Fragment-based drug discovery
6.1.3.2 Bioinformatics & cheminformatics
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR HIGH-THROUGHPUT SCREENING PATENTS, 2015–2025
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
6.5.1 BEST PRACTICES IN HTS WORKFLOW
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
9 HIGH-THROUGHPUT SCREENING MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 PRODUCTS
9.2.1 RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE MARKET GROWTH
9.3 SERVICES
9.3.1 RISING OUTSOURCING OF ASSAY DEVELOPMENT, PRIMARY SCREENING, AND DATA ANALYSIS TO DRIVE GROWTH OF HTS SERVICES MARKET
10 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TYPE
10.1 INTRODUCTION
10.2 REAGENTS, KITS, AND CONSUMABLES
10.2.1 SCREENING ASSAY KITS
10.2.1.1 Cell-based assays
10.2.1.1.1 Cell viability assays
10.2.1.1.1.1 Increasing use of viability readouts across oncology and toxicity screening to sustain assay kit demand
10.2.1.1.2 Cytotoxicity assays
10.2.1.1.2.1 Rising focus on early toxicity detection to improve lead selection and reduce drug development risk
10.2.1.1.3 Reporter gene assays
10.2.1.1.3.1 Growing use of pathway-specific functional readouts to strengthen reporter gene assay adoption
10.2.1.1.4 Other cell-based assays
10.2.1.2 Biochemical assays
10.2.1.2.1 Enzyme assays
10.2.1.2.1.1 Broad use of enzyme activity profiling in target-based drug discovery to sustain demand for enzyme assay kits
10.2.1.2.2 Kinase assays
10.2.1.2.2.1 Continued investment in targeted kinase inhibitor discovery to drive kinase assay kit demand
10.2.1.2.3 Binding assays
10.2.1.2.3.1 Rising use of target engagement and affinity profiling to improve hit validation quality
10.2.1.2.4 Other biochemical assays
10.2.1.3 Other assays & kits
10.2.2 BIOLOGICAL & CELL CULTURE REAGENTS
10.2.2.1 Rising use of disease-relevant cellular models to strengthen demand for biological and cell culture reagents
10.2.3 COMPOUND LIBRARIES
10.2.3.1 Expansion of focused and repurpose libraries to support compound library demand
10.2.4 DETECTION REAGENTS
10.2.4.1 Increasing adoption of fluorescence, luminescence, and biomarker-based readouts to drive detection reagent use
10.2.5 3D CELL CULTURE PRODUCTS
10.2.5.1 Scaffold-based 3D cell culture products
10.2.5.1.1 Rising demand for matrix-supported disease models to drive scaffold-based 3D culture product growth
10.2.5.2 Scaffold-free 3D cell culture products
10.2.5.2.1 Increasing use of spheroid-based screening to support scaffold-free 3D culture product adoption
10.2.5.3 Other 3D cell culture products
10.2.6 OTHER HTS CONSUMABLES
10.3 INSTRUMENTS
10.3.1 DETECTION & IMAGING SYSTEMS
10.3.1.1 Microplate readers
10.3.1.1.1 Growing use of multiplexed biochemical and cell-based assays to support microplate reader demand
10.3.1.2 High-content screening (HCS) & imaging systems
10.3.1.2.1 Increasing adoption of phenotypic screening and AI-based cellular analysis to drive growth of HCS systems
10.3.1.3 Cell analysis systems
10.3.1.3.1 Growing use of cell-based screening and functional biology assays to strengthen demand for cell analysis systems
10.3.1.4 Label-free detection systems
10.3.1.4.1 Rising need for real-time biomolecular interaction analysis to support adoption of label-free detection systems
10.3.1.5 Microfluidic & miniaturized screening systems
10.3.1.5.1 Assay miniaturization to drive adoption of microfluidic screening systems
10.3.2 LIQUID HANDLING & AUTOMATION SYSTEMS
10.3.2.1 Increasing assay miniaturization and workflow standardization to drive growth of liquid handling & automation systems
10.3.3 ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS
10.3.3.1 Rising deployment of end-to-end laboratory automation systems to accelerate robotic HTS platform adoption
10.3.4 OTHER HTS INSTRUMENTS
10.4 SOFTWARE & INFORMATICS
10.4.1 BIOINFORMATICS TOOLS TO HELP TURN RAW DATA INTO MEANINGFUL INSIGHTS
11 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TECHNOLOGY
11.1 INTRODUCTION
11.2 CELL-BASED SCREENING TECHNOLOGIES
11.2.1 INCREASING ADOPTION OF PHYSIOLOGICALLY RELEVANT PHENOTYPIC SCREENING WORKFLOWS TO STRENGTHEN CELL-BASED TECHNOLOGY DEMAND
11.3 ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES
11.3.1 GROWING DEMAND FOR SCALABLE ROBOTIC INFRASTRUCTURE & INTEGRATED AUTOMATION PLATFORMS TO SUPPORT MARKET GROWTH
11.4 HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES
11.4.1 RISING ADOPTION OF AI-POWERED PHENOTYPIC IMAGING AND MULTIPARAMETRIC CELLULAR PROFILING TO ACCELERATE HCS TECHNOLOGY GROWTH
11.5 BIOCHEMICAL SCREENING TECHNOLOGIES
11.5.1 CONTINUED EXPANSION OF TARGET-BASED DRUG DISCOVERY PROGRAMS TO SUSTAIN BIOCHEMICAL SCREENING PRODUCT DEMAND
11.6 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES
11.6.1 RISING ADOPTION OF ORGANOIDS, SPHEROIDS, AND TISSUE-LIKE SCREENING SYSTEMS TO ACCELERATE 3D CELLULAR TECHNOLOGY GROWTH
11.7 LABEL-FREE SCREENING TECHNOLOGIES
11.7.1 INCREASING USE OF REAL-TIME BINDING KINETICS AND BIOPHYSICAL PROFILING TO SUPPORT LABEL-FREE SCREENING ADOPTION
11.8 OTHER HTS TECHNOLOGIES
12 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY WORKFLOW
12.1 INTRODUCTION
12.2 PRIMARY SCREENING
12.2.1 LARGE-SCALE COMPOUND SCREENING REQUIREMENTS TO SUSTAIN PRODUCT DEMAND ACROSS PRIMARY HTS WORKFLOWS
12.3 ASSAY DEVELOPMENT & OPTIMIZATION
12.3.1 RISING NEED FOR ROBUST, MINIATURIZED, AND AUTOMATION-COMPATIBLE ASSAYS TO SUPPORT ASSAY DEVELOPMENT PRODUCT DEMAND
12.4 HIT CONFIRMATION/SECONDARY SCREENING
12.4.1 RISING FOCUS ON HIT QUALITY ASSESSMENT AND FALSE-POSITIVE REDUCTION TO SUPPORT SECONDARY SCREENING PRODUCT DEMAND
12.5 DATA ANALYSIS & HIT IDENTIFICATION
12.5.1 INCREASING INTEGRATION OF AI-DRIVEN ANALYTICS AND IMAGE-BASED SCREENING DATA TO ACCELERATE HIT IDENTIFICATION WORKFLOWS
12.6 COMPOUND LIBRARY PREPARATION
12.6.1 EXPANSION OF LARGE-SCALE AND FOCUSED SCREENING LIBRARIES TO STRENGTHEN DEMAND FOR COMPOUND PREPARATION PRODUCTS
12.7 HIT VALIDATION & CHARACTERIZATION
12.7.1 GROWING FOCUS ON PHENOTYPIC CHARACTERIZATION WORKFLOWS TO DRIVE HIT VALIDATION PRODUCT DEMAND
13 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1 SUSTAINED BIOPHARMA R&D INVESTMENT AND AUTOMATION-LED DRUG DISCOVERY TO DRIVE HTS PRODUCT ADOPTION
13.3 CROS & CDMOS
13.3.1 RISING DISCOVERY OUTSOURCING AND CRO PLATFORM EXPANSION TO ACCELERATE HTS PRODUCT DEMAND
13.4 ACADEMIC & RESEARCH INSTITUTES
13.4.1 PUBLIC RESEARCH FUNDING AND TRANSLATIONAL BIOLOGY PROGRAMS TO SUPPORT HTS PRODUCT UPTAKE IN RESEARCH INSTITUTES
13.5 OTHER END USERS
14 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY TYPE
14.1 INTRODUCTION
14.2 PRIMARY SCREENING SERVICES
14.2.1 RISING HIGH-VOLUME SCREENING REQUIREMENTS TO DRIVE GROWTH OF PRIMARY HTS SCREENING SERVICES
14.3 ASSAY DEVELOPMENT & OPTIMIZATION SERVICES
14.3.1 INCREASING DEMAND FOR CUSTOMIZED AND MINIATURIZED ASSAYS TO SUPPORT ASSAY DEVELOPMENT SERVICE ADOPTION
14.4 SECONDARY SCREENING & HIT CONFIRMATION SERVICES
14.4.1 INCREASING EMPHASIS ON HIT VALIDATION AND SELECTIVITY ASSESSMENT TO SUPPORT SECONDARY SCREENING SERVICES
14.5 HIT VALIDATION & CHARACTERIZATION SERVICES
14.5.1 GROWING NEED FOR MECHANISM-OF-ACTION PROFILING TO STRENGTHEN HIT CHARACTERIZATION SERVICE ADOPTION
14.6 COMPOUND LIBRARY MANAGEMENT SERVICES
14.6.1 EXPANSION OF LARGE-SCALE SCREENING LIBRARIES TO STRENGTHEN DEMAND FOR COMPOUND MANAGEMENT SERVICES
14.7 DATA ANALYSIS & INFORMATICS SERVICES
14.7.1 GROWING ADOPTION OF AI-ENABLED SCREENING ANALYTICS AND IMAGE-BASED DATA INTERPRETATION TO DRIVE HTS INFORMATICS SERVICES GROWTH
14.8 OTHER HTS SERVICES
15 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY END USER
15.1 INTRODUCTION
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.2.1 INCREASING COMPLEXITY OF DRUG DISCOVERY WORKFLOWS TO STRENGTHEN OUTSOURCING OF HTS SERVICES BY PHARMA AND BIOTECH COMPANIES
15.3 ACADEMIC & RESEARCH INSTITUTES
15.3.1 LIMITED IN-HOUSE AUTOMATION CAPACITY TO DRIVE ACADEMIC OUTSOURCING OF HTS SERVICES
15.4 OTHER END USERS
16 HIGH-THROUGHPUT SCREENING MARKET, BY APPLICATION
16.1 INTRODUCTION
16.2 DRUG DISCOVERY & DEVELOPMENT
16.2.1 INCREASING PHARMACEUTICAL R&D INVESTMENTS AND EXPANSION OF TARGET-BASED AND PHENOTYPIC DRUG DISCOVERY PROGRAMS TO DRIVE MARKET GROWTH
16.3 BASIC RESEARCH & FUNCTIONAL GENOMICS
16.3.1 GROWING ADOPTION OF CRISPR SCREENING, FUNCTIONAL GENOMICS, AND DISEASE PATHWAY CHARACTERIZATION TO DRIVE HTS DEMAND
16.4 TOXICOLOGY & SAFETY SCREENING
16.4.1 INCREASING EMPHASIS ON PREDICTIVE TOXICOLOGY AND REGULATORY PRESSURE TO REDUCE ANIMAL TESTING TO ACCELERATE HTS ADOPTION
16.5 PRECISION MEDICINE & BIOMARKER DISCOVERY
16.5.1 EXPANSION OF BIOMARKER-GUIDED THERAPEUTICS AND PERSONALIZED MEDICINE PIPELINES TO DRIVE RAPID GROWTH IN PRECISION MEDICINE SCREENING APPLICATIONS
16.6 STEM CELL & REGENERATIVE MEDICINE RESEARCH
16.6.1 GROWING DEVELOPMENT OF CELL THERAPIES AND REGENERATIVE MEDICINE PRODUCTS IS SUPPORTING HTS ADOPTION IN STEM CELL RESEARCH
16.7 OTHER APPLICATIONS
17 HIGH-THROUGHPUT SCREENING MARKET, BY REGION
17.1 INTRODUCTION
17.2 NORTH AMERICA
17.2.1 US
17.2.1.1 Advanced automation, strong drug discovery infrastructure, and AI-enabled screening workflows to support market growth
17.2.2 CANADA
17.2.2.1 Academic screening infrastructure to support market growth
17.3 EUROPE
17.3.1 GERMANY
17.3.1.1 Increasing product launches and investments to boost market growth
17.3.2 UK
17.3.2.1 Industrial-scale screening access and academic HTS infrastructure to support market
17.3.3 FRANCE
17.3.3.1 Large pharmaceutical R&D expenditure to drive market growth
17.3.4 ITALY
17.3.4.1 Functional genomics and automated screening platforms to fuel growth
17.3.5 SPAIN
17.3.5.1 Academic screening platforms, chemical biology networks, and assay automation to boost market
17.3.6 REST OF EUROPE
17.4 ASIA PACIFIC
17.4.1 CHINA
17.4.1.1 Automation-led drug discovery and CRO-led screening capacity expansion to support growth of market
17.4.2 JAPAN
17.4.2.1 Advanced screening platforms and integrated drug discovery partnerships to support market growth
17.4.3 INDIA
17.4.3.1 Automation-led CRO expansion and biopharma R&D infrastructure growth to fuel market
17.4.4 AUSTRALIA
17.4.4.1 Robotic screening infrastructure and translational drug discovery programs to drive market growth
17.4.5 SOUTH KOREA
17.4.5.1 AI-enhanced screening platforms and translational R&D collaborations to favor market growth
17.4.6 REST OF ASIA PACIFIC (ROAPAC)
17.5 LATIN AMERICA
17.5.1 BRAZIL
17.5.1.1 Automated bioassay infrastructure and disease-focused discovery programs to drive growth
17.5.2 MEXICO
17.5.2.1 Cost-efficient discovery capacity, antimicrobial research, and automated assay adoption to drive growth
17.5.3 REST OF LATIN AMERICA
17.6 MIDDLE EAST
17.6.1 GCC COUNTRIES
17.6.1.1 Saudi Arabia
17.6.1.1.1 Growing pharmaceuticals industry to support market growth
17.6.1.2 UAE
17.6.1.2.1 Precision medicine investment, automated laboratory infrastructure, and AI-enabled discovery workflows to boost market growth
17.6.1.3 Rest of GCC Countries
17.6.2 REST OF MIDDLE EAST
17.7 AFRICA
17.7.1 INFECTIOUS DISEASE RESEARCH AND SHARED DISCOVERY NETWORKS TO AID MARKET GROWTH
18 COMPETITIVE LANDSCAPE
18.1 OVERVIEW
18.2 KEY PLAYER STRATEGY/RIGHT TO WIN
18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
18.3 REVENUE ANALYSIS, 2021–2025
18.4 MARKET SHARE ANALYSIS, 2025
18.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2025
18.5.1 STARS
18.5.2 EMERGING LEADERS
18.5.3 PERVASIVE PLAYERS
18.5.4 PARTICIPANTS
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
18.5.5.1 Company footprint
18.5.5.2 Region footprint
18.5.5.3 Offering footprint
18.5.5.4 Product type footprint
18.5.5.5 Application footprint
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.6.1 PROGRESSIVE COMPANIES
18.6.2 RESPONSIVE COMPANIES
18.6.3 DYNAMIC COMPANIES
18.6.4 STARTING BLOCKS
18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
18.6.5.1 Detailed list of key startups/SMEs
18.6.5.2 Competitive benchmarking of key startups/SMEs
18.7 COMPANY VALUATION & FINANCIAL METRICS
18.7.1 FINANCIAL METRICS
18.7.2 COMPANY VALUATION
18.8 BRAND/PRODUCT/SERVICE COMPARISON
18.9 COMPETITIVE SCENARIO
18.9.1 PRODUCT LAUNCHES
18.9.2 DEALS
18.9.3 EXPANSIONS
19 COMPANY PROFILES
19.1 KEY PLAYERS
19.1.1 THERMO FISHER SCIENTIFIC INC.
19.1.1.1 Business overview
19.1.1.2 Products & services offered
19.1.1.3 Recent developments
19.1.1.3.1 Product launches
19.1.1.3.2 Deals
19.1.1.3.3 Expansions
19.1.1.4 MnM view
19.1.1.4.1 Right to win
19.1.1.4.2 Strategic choices
19.1.1.4.3 Weaknesses & competitive threats
19.1.2 DANAHER CORPORATION
19.1.2.1 Business overview
19.1.2.2 Products & services offered
19.1.2.3 Recent developments
19.1.2.3.1 Product & service launches
19.1.2.3.2 Deals
19.1.2.4 MnM view
19.1.2.4.1 Right to win
19.1.2.4.2 Strategic choices
19.1.2.4.3 Weaknesses & competitive threats
19.1.3 MERCK KGAA
19.1.3.1 Business overview
19.1.3.2 Products & services offered
19.1.3.3 Recent developments
19.1.3.3.1 Deals
19.1.3.3.2 Expansions
19.1.3.3.3 Other developments
19.1.3.4 MnM view
19.1.3.4.1 Right to win
19.1.3.4.2 Strategic choices
19.1.3.4.3 Weaknesses & competitive threats
19.1.4 AGILENT TECHNOLOGIES, INC.
19.1.4.1 Business overview
19.1.4.2 Products & services offered
19.1.4.3 Recent developments
19.1.4.3.1 Product launches & upgrades
19.1.4.3.2 Deals
19.1.4.3.3 Expansions
19.1.4.3.4 Other developments
19.1.4.4 MnM view
19.1.4.4.1 Right to win
19.1.4.4.2 Strategic choices
19.1.4.4.3 Weaknesses & competitive threats
19.1.5 REVVITY, INC.
19.1.5.1 Business overview
19.1.5.2 Products & services offered
19.1.5.3 Recent developments
19.1.5.3.1 Product launches
19.1.5.3.2 Deals
19.1.5.4 MnM view
19.1.5.4.1 Right to win
19.1.5.4.2 Strategic choices
19.1.5.4.3 Weaknesses & competitive threats
19.1.6 TECAN GROUP LTD.
19.1.6.1 Business overview
19.1.6.2 Products & service offered
19.1.6.3 Recent developments
19.1.6.3.1 Product launches
19.1.6.3.2 Deals
19.1.7 BIO-RAD LABORATORIES, INC.
19.1.7.1 Business overview
19.1.7.2 Products & services offered
19.1.7.3 Recent developments
19.1.7.3.1 Product launches
19.1.8 CORNING INCORPORATED
19.1.8.1 Business overview
19.1.8.2 Products & services offered
19.1.9 METTLER-TOLEDO INTERNATIONAL INC.
19.1.9.1 Business overview
19.1.9.2 Products & services offered
19.1.10 LONZA GROUP
19.1.10.1 Business overview
19.1.10.2 Products & services offered
19.1.11 WATERS CORPORATION
19.1.11.1 Business overview
19.1.11.2 Products & services offered
19.1.11.3 Recent developments
19.1.11.3.1 Product launches
19.1.11.3.2 Deals
19.1.12 SARTORIUS AG
19.1.12.1 Business overview
19.1.12.2 Products & services offered
19.1.12.3 Recent developments
19.1.12.3.1 Product launches
19.1.12.3.2 Deals
19.1.12.3.3 Expansions
19.1.13 EPPENDORF SE
19.1.13.1 Business overview
19.1.13.2 Products & services offered
19.1.13.3 Recent developments
19.1.13.3.1 Product launches
19.1.13.3.2 Deals
19.1.13.3.3 Expansions
19.1.14 PORVAIR PLC
19.1.14.1 Business overview
19.1.14.2 Products & services offered
19.1.15 GREINER AG
19.1.15.1 Business overview
19.1.15.2 Products & services offered
19.1.16 CHARLES RIVER LABORATORIES
19.1.16.1 Business overview
19.1.16.2 products & services offered
19.1.16.3 Recent developments
19.1.16.3.1 Deals
19.1.17 EUROFINS SCIENTIFIC
19.1.17.1 Business overview
19.1.17.2 Products & services offered
19.1.17.3 Recent developments
19.1.17.3.1 Service launches
19.1.17.3.2 Deals
19.1.17.3.3 Expansions
19.1.18 HAMILTON COMPANY
19.1.18.1 Business overview
19.1.18.2 Products & services offered
19.1.18.3 Recent developments
19.1.18.3.1 Product launches
19.1.18.3.2 Deals
19.1.19 AURORA BIOMED INC.
19.1.19.1 Business overview
19.1.19.2 Products & services offered
19.1.20 GILSON INCORPORATED
19.1.20.1 Business overview
19.1.20.2 Products & services offered
19.1.21 BRAND GMBH + CO KG
19.1.21.1 Business overview
19.1.21.2 Products & services offered
19.2 OTHER PLAYERS
19.2.1 BMG LABTECH GMBH
19.2.2 DIANA BIOTECHNOLOGIES, A.S.
19.2.3 CREATIVE BIOLABS
19.2.4 HIGHRES BIOSOLUTIONS
19.2.5 BIOMAT SRL
19.2.6 AXXAM S.P.A.
19.2.7 SYGNATURE DISCOVERY LIMITED
19.2.8 CROWN BIOSCIENCE
20 RESEARCH METHODOLOGY
20.1 RESEARCH DATA
20.1.1 SECONDARY DATA
20.1.1.1 Key secondary sources
20.1.1.2 Key data from secondary research
20.1.2 PRIMARY DATA
20.1.2.1 Key primary participants
20.1.2.2 Breakdown of primary interviews
20.1.2.3 Key data from primary sources
20.2 MARKET SIZE ESTIMATION
20.2.1 GLOBAL HIGH-THROUGHPUT SCREENING MARKET ESTIMATION, 2025
20.2.1.1 Approach 1: Company revenue analysis-based estimation
(bottom-up)
20.2.1.2 Approach 2: Primary research
20.2.1.2.1 Key industry insights
20.2.1.3 Approach 3: MnM repository analysis
20.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
20.3 MARKET GROWTH RATE PROJECTIONS
20.4 DATA TRIANGULATION
20.5 RESEARCH ASSUMPTIONS
20.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT
21 APPENDIX
21.1 DISCUSSION GUIDE
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3 CUSTOMIZATION OPTIONS
21.4 RELATED REPORTS
21.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN HIGH-THROUGHPUT SCREENING MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 HIGH-THROUGHPUT SCREENING MARKET OVERVIEW
3.2 NORTH AMERICA: HIGH-THROUGHPUT SCREENING MARKET, BY PRODUCT TYPE AND COUNTRY
3.3 HIGH-THROUGHPUT SCREENING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET SHARE, BY END USER, 2026 VS 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing adoption of open innovative models
4.2.1.2 Technological advancements
4.2.1.3 Growing R&D funding and increasing public & private investments
4.2.1.4 Growing adoption of lab automation & robotic screening platforms
4.2.1.5 Increasing outsourcing of screening activities to CROs & CDMOs
4.2.2 RESTRAINTS
4.2.2.1 High costs associated with HTS instruments
4.2.2.2 Complexity in assay development and validation
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing adoption of HTS technologies in emerging markets
4.2.3.2 Growing application of HTS in drug repurposing and personalized medicine
4.2.3.3 Expansion of CRISPR, RNAi, and functional genomics screening
4.2.4 CHALLENGES
4.2.4.1 Complexity in data management and analysis
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 INTENSITY OF COMPETITIVE RIVALRY
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 THREAT OF NEW ENTRANTS
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL HIGH-THROUGHPUT SCREENING INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY KEY PLAYER, 2023–2025
5.5.2 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY REGION, 2023–2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT SCENARIO (HS CODE 902730 & 902781)
5.6.2 EXPORT SCENARIO (HS CODE 902730& 902781)
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING SCENARIO
5.10 IMPACT OF 2025 US TARIFFS ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRIES/REGIONS
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia Pacific
5.10.5 IMPACT ON END-USE INDUSTRIES
5.10.5.1 Pharmaceutical & biotechnology companies
5.10.5.2 CROs & CDMOs
5.10.5.3 Academic & research institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS
6.1 TECHNOLOGICAL ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 High-content screening
6.1.1.2 Label-free detection
6.1.1.3 Microfluidics
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Laboratory automation & robotic integration
6.1.2.2 Mass spectrometry
6.1.2.3 Flow cytometry
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Fragment-based drug discovery
6.1.3.2 Bioinformatics & cheminformatics
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR HIGH-THROUGHPUT SCREENING PATENTS, 2015–2025
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
6.5.1 BEST PRACTICES IN HTS WORKFLOW
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
9 HIGH-THROUGHPUT SCREENING MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 PRODUCTS
9.2.1 RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE MARKET GROWTH
9.3 SERVICES
9.3.1 RISING OUTSOURCING OF ASSAY DEVELOPMENT, PRIMARY SCREENING, AND DATA ANALYSIS TO DRIVE GROWTH OF HTS SERVICES MARKET
10 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TYPE
10.1 INTRODUCTION
10.2 REAGENTS, KITS, AND CONSUMABLES
10.2.1 SCREENING ASSAY KITS
10.2.1.1 Cell-based assays
10.2.1.1.1 Cell viability assays
10.2.1.1.1.1 Increasing use of viability readouts across oncology and toxicity screening to sustain assay kit demand
10.2.1.1.2 Cytotoxicity assays
10.2.1.1.2.1 Rising focus on early toxicity detection to improve lead selection and reduce drug development risk
10.2.1.1.3 Reporter gene assays
10.2.1.1.3.1 Growing use of pathway-specific functional readouts to strengthen reporter gene assay adoption
10.2.1.1.4 Other cell-based assays
10.2.1.2 Biochemical assays
10.2.1.2.1 Enzyme assays
10.2.1.2.1.1 Broad use of enzyme activity profiling in target-based drug discovery to sustain demand for enzyme assay kits
10.2.1.2.2 Kinase assays
10.2.1.2.2.1 Continued investment in targeted kinase inhibitor discovery to drive kinase assay kit demand
10.2.1.2.3 Binding assays
10.2.1.2.3.1 Rising use of target engagement and affinity profiling to improve hit validation quality
10.2.1.2.4 Other biochemical assays
10.2.1.3 Other assays & kits
10.2.2 BIOLOGICAL & CELL CULTURE REAGENTS
10.2.2.1 Rising use of disease-relevant cellular models to strengthen demand for biological and cell culture reagents
10.2.3 COMPOUND LIBRARIES
10.2.3.1 Expansion of focused and repurpose libraries to support compound library demand
10.2.4 DETECTION REAGENTS
10.2.4.1 Increasing adoption of fluorescence, luminescence, and biomarker-based readouts to drive detection reagent use
10.2.5 3D CELL CULTURE PRODUCTS
10.2.5.1 Scaffold-based 3D cell culture products
10.2.5.1.1 Rising demand for matrix-supported disease models to drive scaffold-based 3D culture product growth
10.2.5.2 Scaffold-free 3D cell culture products
10.2.5.2.1 Increasing use of spheroid-based screening to support scaffold-free 3D culture product adoption
10.2.5.3 Other 3D cell culture products
10.2.6 OTHER HTS CONSUMABLES
10.3 INSTRUMENTS
10.3.1 DETECTION & IMAGING SYSTEMS
10.3.1.1 Microplate readers
10.3.1.1.1 Growing use of multiplexed biochemical and cell-based assays to support microplate reader demand
10.3.1.2 High-content screening (HCS) & imaging systems
10.3.1.2.1 Increasing adoption of phenotypic screening and AI-based cellular analysis to drive growth of HCS systems
10.3.1.3 Cell analysis systems
10.3.1.3.1 Growing use of cell-based screening and functional biology assays to strengthen demand for cell analysis systems
10.3.1.4 Label-free detection systems
10.3.1.4.1 Rising need for real-time biomolecular interaction analysis to support adoption of label-free detection systems
10.3.1.5 Microfluidic & miniaturized screening systems
10.3.1.5.1 Assay miniaturization to drive adoption of microfluidic screening systems
10.3.2 LIQUID HANDLING & AUTOMATION SYSTEMS
10.3.2.1 Increasing assay miniaturization and workflow standardization to drive growth of liquid handling & automation systems
10.3.3 ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS
10.3.3.1 Rising deployment of end-to-end laboratory automation systems to accelerate robotic HTS platform adoption
10.3.4 OTHER HTS INSTRUMENTS
10.4 SOFTWARE & INFORMATICS
10.4.1 BIOINFORMATICS TOOLS TO HELP TURN RAW DATA INTO MEANINGFUL INSIGHTS
11 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TECHNOLOGY
11.1 INTRODUCTION
11.2 CELL-BASED SCREENING TECHNOLOGIES
11.2.1 INCREASING ADOPTION OF PHYSIOLOGICALLY RELEVANT PHENOTYPIC SCREENING WORKFLOWS TO STRENGTHEN CELL-BASED TECHNOLOGY DEMAND
11.3 ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES
11.3.1 GROWING DEMAND FOR SCALABLE ROBOTIC INFRASTRUCTURE & INTEGRATED AUTOMATION PLATFORMS TO SUPPORT MARKET GROWTH
11.4 HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES
11.4.1 RISING ADOPTION OF AI-POWERED PHENOTYPIC IMAGING AND MULTIPARAMETRIC CELLULAR PROFILING TO ACCELERATE HCS TECHNOLOGY GROWTH
11.5 BIOCHEMICAL SCREENING TECHNOLOGIES
11.5.1 CONTINUED EXPANSION OF TARGET-BASED DRUG DISCOVERY PROGRAMS TO SUSTAIN BIOCHEMICAL SCREENING PRODUCT DEMAND
11.6 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES
11.6.1 RISING ADOPTION OF ORGANOIDS, SPHEROIDS, AND TISSUE-LIKE SCREENING SYSTEMS TO ACCELERATE 3D CELLULAR TECHNOLOGY GROWTH
11.7 LABEL-FREE SCREENING TECHNOLOGIES
11.7.1 INCREASING USE OF REAL-TIME BINDING KINETICS AND BIOPHYSICAL PROFILING TO SUPPORT LABEL-FREE SCREENING ADOPTION
11.8 OTHER HTS TECHNOLOGIES
12 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY WORKFLOW
12.1 INTRODUCTION
12.2 PRIMARY SCREENING
12.2.1 LARGE-SCALE COMPOUND SCREENING REQUIREMENTS TO SUSTAIN PRODUCT DEMAND ACROSS PRIMARY HTS WORKFLOWS
12.3 ASSAY DEVELOPMENT & OPTIMIZATION
12.3.1 RISING NEED FOR ROBUST, MINIATURIZED, AND AUTOMATION-COMPATIBLE ASSAYS TO SUPPORT ASSAY DEVELOPMENT PRODUCT DEMAND
12.4 HIT CONFIRMATION/SECONDARY SCREENING
12.4.1 RISING FOCUS ON HIT QUALITY ASSESSMENT AND FALSE-POSITIVE REDUCTION TO SUPPORT SECONDARY SCREENING PRODUCT DEMAND
12.5 DATA ANALYSIS & HIT IDENTIFICATION
12.5.1 INCREASING INTEGRATION OF AI-DRIVEN ANALYTICS AND IMAGE-BASED SCREENING DATA TO ACCELERATE HIT IDENTIFICATION WORKFLOWS
12.6 COMPOUND LIBRARY PREPARATION
12.6.1 EXPANSION OF LARGE-SCALE AND FOCUSED SCREENING LIBRARIES TO STRENGTHEN DEMAND FOR COMPOUND PREPARATION PRODUCTS
12.7 HIT VALIDATION & CHARACTERIZATION
12.7.1 GROWING FOCUS ON PHENOTYPIC CHARACTERIZATION WORKFLOWS TO DRIVE HIT VALIDATION PRODUCT DEMAND
13 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY END USER
13.1 INTRODUCTION
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1 SUSTAINED BIOPHARMA R&D INVESTMENT AND AUTOMATION-LED DRUG DISCOVERY TO DRIVE HTS PRODUCT ADOPTION
13.3 CROS & CDMOS
13.3.1 RISING DISCOVERY OUTSOURCING AND CRO PLATFORM EXPANSION TO ACCELERATE HTS PRODUCT DEMAND
13.4 ACADEMIC & RESEARCH INSTITUTES
13.4.1 PUBLIC RESEARCH FUNDING AND TRANSLATIONAL BIOLOGY PROGRAMS TO SUPPORT HTS PRODUCT UPTAKE IN RESEARCH INSTITUTES
13.5 OTHER END USERS
14 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY TYPE
14.1 INTRODUCTION
14.2 PRIMARY SCREENING SERVICES
14.2.1 RISING HIGH-VOLUME SCREENING REQUIREMENTS TO DRIVE GROWTH OF PRIMARY HTS SCREENING SERVICES
14.3 ASSAY DEVELOPMENT & OPTIMIZATION SERVICES
14.3.1 INCREASING DEMAND FOR CUSTOMIZED AND MINIATURIZED ASSAYS TO SUPPORT ASSAY DEVELOPMENT SERVICE ADOPTION
14.4 SECONDARY SCREENING & HIT CONFIRMATION SERVICES
14.4.1 INCREASING EMPHASIS ON HIT VALIDATION AND SELECTIVITY ASSESSMENT TO SUPPORT SECONDARY SCREENING SERVICES
14.5 HIT VALIDATION & CHARACTERIZATION SERVICES
14.5.1 GROWING NEED FOR MECHANISM-OF-ACTION PROFILING TO STRENGTHEN HIT CHARACTERIZATION SERVICE ADOPTION
14.6 COMPOUND LIBRARY MANAGEMENT SERVICES
14.6.1 EXPANSION OF LARGE-SCALE SCREENING LIBRARIES TO STRENGTHEN DEMAND FOR COMPOUND MANAGEMENT SERVICES
14.7 DATA ANALYSIS & INFORMATICS SERVICES
14.7.1 GROWING ADOPTION OF AI-ENABLED SCREENING ANALYTICS AND IMAGE-BASED DATA INTERPRETATION TO DRIVE HTS INFORMATICS SERVICES GROWTH
14.8 OTHER HTS SERVICES
15 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY END USER
15.1 INTRODUCTION
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.2.1 INCREASING COMPLEXITY OF DRUG DISCOVERY WORKFLOWS TO STRENGTHEN OUTSOURCING OF HTS SERVICES BY PHARMA AND BIOTECH COMPANIES
15.3 ACADEMIC & RESEARCH INSTITUTES
15.3.1 LIMITED IN-HOUSE AUTOMATION CAPACITY TO DRIVE ACADEMIC OUTSOURCING OF HTS SERVICES
15.4 OTHER END USERS
16 HIGH-THROUGHPUT SCREENING MARKET, BY APPLICATION
16.1 INTRODUCTION
16.2 DRUG DISCOVERY & DEVELOPMENT
16.2.1 INCREASING PHARMACEUTICAL R&D INVESTMENTS AND EXPANSION OF TARGET-BASED AND PHENOTYPIC DRUG DISCOVERY PROGRAMS TO DRIVE MARKET GROWTH
16.3 BASIC RESEARCH & FUNCTIONAL GENOMICS
16.3.1 GROWING ADOPTION OF CRISPR SCREENING, FUNCTIONAL GENOMICS, AND DISEASE PATHWAY CHARACTERIZATION TO DRIVE HTS DEMAND
16.4 TOXICOLOGY & SAFETY SCREENING
16.4.1 INCREASING EMPHASIS ON PREDICTIVE TOXICOLOGY AND REGULATORY PRESSURE TO REDUCE ANIMAL TESTING TO ACCELERATE HTS ADOPTION
16.5 PRECISION MEDICINE & BIOMARKER DISCOVERY
16.5.1 EXPANSION OF BIOMARKER-GUIDED THERAPEUTICS AND PERSONALIZED MEDICINE PIPELINES TO DRIVE RAPID GROWTH IN PRECISION MEDICINE SCREENING APPLICATIONS
16.6 STEM CELL & REGENERATIVE MEDICINE RESEARCH
16.6.1 GROWING DEVELOPMENT OF CELL THERAPIES AND REGENERATIVE MEDICINE PRODUCTS IS SUPPORTING HTS ADOPTION IN STEM CELL RESEARCH
16.7 OTHER APPLICATIONS
17 HIGH-THROUGHPUT SCREENING MARKET, BY REGION
17.1 INTRODUCTION
17.2 NORTH AMERICA
17.2.1 US
17.2.1.1 Advanced automation, strong drug discovery infrastructure, and AI-enabled screening workflows to support market growth
17.2.2 CANADA
17.2.2.1 Academic screening infrastructure to support market growth
17.3 EUROPE
17.3.1 GERMANY
17.3.1.1 Increasing product launches and investments to boost market growth
17.3.2 UK
17.3.2.1 Industrial-scale screening access and academic HTS infrastructure to support market
17.3.3 FRANCE
17.3.3.1 Large pharmaceutical R&D expenditure to drive market growth
17.3.4 ITALY
17.3.4.1 Functional genomics and automated screening platforms to fuel growth
17.3.5 SPAIN
17.3.5.1 Academic screening platforms, chemical biology networks, and assay automation to boost market
17.3.6 REST OF EUROPE
17.4 ASIA PACIFIC
17.4.1 CHINA
17.4.1.1 Automation-led drug discovery and CRO-led screening capacity expansion to support growth of market
17.4.2 JAPAN
17.4.2.1 Advanced screening platforms and integrated drug discovery partnerships to support market growth
17.4.3 INDIA
17.4.3.1 Automation-led CRO expansion and biopharma R&D infrastructure growth to fuel market
17.4.4 AUSTRALIA
17.4.4.1 Robotic screening infrastructure and translational drug discovery programs to drive market growth
17.4.5 SOUTH KOREA
17.4.5.1 AI-enhanced screening platforms and translational R&D collaborations to favor market growth
17.4.6 REST OF ASIA PACIFIC (ROAPAC)
17.5 LATIN AMERICA
17.5.1 BRAZIL
17.5.1.1 Automated bioassay infrastructure and disease-focused discovery programs to drive growth
17.5.2 MEXICO
17.5.2.1 Cost-efficient discovery capacity, antimicrobial research, and automated assay adoption to drive growth
17.5.3 REST OF LATIN AMERICA
17.6 MIDDLE EAST
17.6.1 GCC COUNTRIES
17.6.1.1 Saudi Arabia
17.6.1.1.1 Growing pharmaceuticals industry to support market growth
17.6.1.2 UAE
17.6.1.2.1 Precision medicine investment, automated laboratory infrastructure, and AI-enabled discovery workflows to boost market growth
17.6.1.3 Rest of GCC Countries
17.6.2 REST OF MIDDLE EAST
17.7 AFRICA
17.7.1 INFECTIOUS DISEASE RESEARCH AND SHARED DISCOVERY NETWORKS TO AID MARKET GROWTH
18 COMPETITIVE LANDSCAPE
18.1 OVERVIEW
18.2 KEY PLAYER STRATEGY/RIGHT TO WIN
18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
18.3 REVENUE ANALYSIS, 2021–2025
18.4 MARKET SHARE ANALYSIS, 2025
18.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2025
18.5.1 STARS
18.5.2 EMERGING LEADERS
18.5.3 PERVASIVE PLAYERS
18.5.4 PARTICIPANTS
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
18.5.5.1 Company footprint
18.5.5.2 Region footprint
18.5.5.3 Offering footprint
18.5.5.4 Product type footprint
18.5.5.5 Application footprint
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.6.1 PROGRESSIVE COMPANIES
18.6.2 RESPONSIVE COMPANIES
18.6.3 DYNAMIC COMPANIES
18.6.4 STARTING BLOCKS
18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
18.6.5.1 Detailed list of key startups/SMEs
18.6.5.2 Competitive benchmarking of key startups/SMEs
18.7 COMPANY VALUATION & FINANCIAL METRICS
18.7.1 FINANCIAL METRICS
18.7.2 COMPANY VALUATION
18.8 BRAND/PRODUCT/SERVICE COMPARISON
18.9 COMPETITIVE SCENARIO
18.9.1 PRODUCT LAUNCHES
18.9.2 DEALS
18.9.3 EXPANSIONS
19 COMPANY PROFILES
19.1 KEY PLAYERS
19.1.1 THERMO FISHER SCIENTIFIC INC.
19.1.1.1 Business overview
19.1.1.2 Products & services offered
19.1.1.3 Recent developments
19.1.1.3.1 Product launches
19.1.1.3.2 Deals
19.1.1.3.3 Expansions
19.1.1.4 MnM view
19.1.1.4.1 Right to win
19.1.1.4.2 Strategic choices
19.1.1.4.3 Weaknesses & competitive threats
19.1.2 DANAHER CORPORATION
19.1.2.1 Business overview
19.1.2.2 Products & services offered
19.1.2.3 Recent developments
19.1.2.3.1 Product & service launches
19.1.2.3.2 Deals
19.1.2.4 MnM view
19.1.2.4.1 Right to win
19.1.2.4.2 Strategic choices
19.1.2.4.3 Weaknesses & competitive threats
19.1.3 MERCK KGAA
19.1.3.1 Business overview
19.1.3.2 Products & services offered
19.1.3.3 Recent developments
19.1.3.3.1 Deals
19.1.3.3.2 Expansions
19.1.3.3.3 Other developments
19.1.3.4 MnM view
19.1.3.4.1 Right to win
19.1.3.4.2 Strategic choices
19.1.3.4.3 Weaknesses & competitive threats
19.1.4 AGILENT TECHNOLOGIES, INC.
19.1.4.1 Business overview
19.1.4.2 Products & services offered
19.1.4.3 Recent developments
19.1.4.3.1 Product launches & upgrades
19.1.4.3.2 Deals
19.1.4.3.3 Expansions
19.1.4.3.4 Other developments
19.1.4.4 MnM view
19.1.4.4.1 Right to win
19.1.4.4.2 Strategic choices
19.1.4.4.3 Weaknesses & competitive threats
19.1.5 REVVITY, INC.
19.1.5.1 Business overview
19.1.5.2 Products & services offered
19.1.5.3 Recent developments
19.1.5.3.1 Product launches
19.1.5.3.2 Deals
19.1.5.4 MnM view
19.1.5.4.1 Right to win
19.1.5.4.2 Strategic choices
19.1.5.4.3 Weaknesses & competitive threats
19.1.6 TECAN GROUP LTD.
19.1.6.1 Business overview
19.1.6.2 Products & service offered
19.1.6.3 Recent developments
19.1.6.3.1 Product launches
19.1.6.3.2 Deals
19.1.7 BIO-RAD LABORATORIES, INC.
19.1.7.1 Business overview
19.1.7.2 Products & services offered
19.1.7.3 Recent developments
19.1.7.3.1 Product launches
19.1.8 CORNING INCORPORATED
19.1.8.1 Business overview
19.1.8.2 Products & services offered
19.1.9 METTLER-TOLEDO INTERNATIONAL INC.
19.1.9.1 Business overview
19.1.9.2 Products & services offered
19.1.10 LONZA GROUP
19.1.10.1 Business overview
19.1.10.2 Products & services offered
19.1.11 WATERS CORPORATION
19.1.11.1 Business overview
19.1.11.2 Products & services offered
19.1.11.3 Recent developments
19.1.11.3.1 Product launches
19.1.11.3.2 Deals
19.1.12 SARTORIUS AG
19.1.12.1 Business overview
19.1.12.2 Products & services offered
19.1.12.3 Recent developments
19.1.12.3.1 Product launches
19.1.12.3.2 Deals
19.1.12.3.3 Expansions
19.1.13 EPPENDORF SE
19.1.13.1 Business overview
19.1.13.2 Products & services offered
19.1.13.3 Recent developments
19.1.13.3.1 Product launches
19.1.13.3.2 Deals
19.1.13.3.3 Expansions
19.1.14 PORVAIR PLC
19.1.14.1 Business overview
19.1.14.2 Products & services offered
19.1.15 GREINER AG
19.1.15.1 Business overview
19.1.15.2 Products & services offered
19.1.16 CHARLES RIVER LABORATORIES
19.1.16.1 Business overview
19.1.16.2 products & services offered
19.1.16.3 Recent developments
19.1.16.3.1 Deals
19.1.17 EUROFINS SCIENTIFIC
19.1.17.1 Business overview
19.1.17.2 Products & services offered
19.1.17.3 Recent developments
19.1.17.3.1 Service launches
19.1.17.3.2 Deals
19.1.17.3.3 Expansions
19.1.18 HAMILTON COMPANY
19.1.18.1 Business overview
19.1.18.2 Products & services offered
19.1.18.3 Recent developments
19.1.18.3.1 Product launches
19.1.18.3.2 Deals
19.1.19 AURORA BIOMED INC.
19.1.19.1 Business overview
19.1.19.2 Products & services offered
19.1.20 GILSON INCORPORATED
19.1.20.1 Business overview
19.1.20.2 Products & services offered
19.1.21 BRAND GMBH + CO KG
19.1.21.1 Business overview
19.1.21.2 Products & services offered
19.2 OTHER PLAYERS
19.2.1 BMG LABTECH GMBH
19.2.2 DIANA BIOTECHNOLOGIES, A.S.
19.2.3 CREATIVE BIOLABS
19.2.4 HIGHRES BIOSOLUTIONS
19.2.5 BIOMAT SRL
19.2.6 AXXAM S.P.A.
19.2.7 SYGNATURE DISCOVERY LIMITED
19.2.8 CROWN BIOSCIENCE
20 RESEARCH METHODOLOGY
20.1 RESEARCH DATA
20.1.1 SECONDARY DATA
20.1.1.1 Key secondary sources
20.1.1.2 Key data from secondary research
20.1.2 PRIMARY DATA
20.1.2.1 Key primary participants
20.1.2.2 Breakdown of primary interviews
20.1.2.3 Key data from primary sources
20.2 MARKET SIZE ESTIMATION
20.2.1 GLOBAL HIGH-THROUGHPUT SCREENING MARKET ESTIMATION, 2025
20.2.1.1 Approach 1: Company revenue analysis-based estimation
(bottom-up)
20.2.1.2 Approach 2: Primary research
20.2.1.2.1 Key industry insights
20.2.1.3 Approach 3: MnM repository analysis
20.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
20.3 MARKET GROWTH RATE PROJECTIONS
20.4 DATA TRIANGULATION
20.5 RESEARCH ASSUMPTIONS
20.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT
21 APPENDIX
21.1 DISCUSSION GUIDE
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3 CUSTOMIZATION OPTIONS
21.4 RELATED REPORTS
21.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 HIGH-THROUGHPUT SCREENING (HTS) MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 HIGH-THROUGHPUT SCREENING (HTS) MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 HIGH-THROUGHPUT SCREENING (HTS) MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 4 HIGH-THROUGHPUT SCREENING (HTS) MARKET: ROLE IN ECOSYSTEM
TABLE 5 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 6 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY REGION, 2023–2025 (USD)
TABLE 7 IMPORT VALUE FOR HS CODE 902730, 2021–2025 (USD THOUSAND)
TABLE 8 IMPORT VOLUME FOR HS CODE 902730, 2021–2025 (TONS)
TABLE 9 IMPORT VALUE FOR HS CODE 902781, 2022–2025 (USD THOUSAND)
TABLE 10 IMPORT VOLUME FOR HS CODE 902781, 2022–2025 (UNITS)
TABLE 11 EXPORT VALUE FOR HS CODE 902730, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 12 EXPORT VOLUME FOR HS CODE 902730, BY COUNTRY, 2021–2025 (TONS)
TABLE 13 EXPORT VALUE FOR HS CODE 902781, 2022–2025 (USD THOUSAND)
TABLE 14 EXPORT VOLUME FOR HS CODE 902781, 2022–2025 (UNITS)
TABLE 15 HIGH-THROUGHPUT SCREENING (HTS) MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 17 HIGH-THROUGHPUT SCREENING (HTS) MARKET: INDICATIVE LIST OF PATENTS, 2026
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
TABLE 19 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN HIGH-THROUGHPUT SCREENING
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 US FOOD AND DRUG ADMINISTRATION: MEDICAL DEVICE CLASSIFICATION
TABLE 25 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
TABLE 27 KEY BUYING CRITERIA, BY END USER
TABLE 28 HIGH-THROUGHPUT SCREENING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 29 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 EUROPE: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 LATIN AMERICA: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 MIDDLE EAST: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 GCC COUNTRIES: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 NORTH AMERICA: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 EUROPE: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 LATIN AMERICA: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 MIDDLE EAST: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 GCC COUNTRIES: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 44 HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 NORTH AMERICA: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 EUROPE: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, 2024–2031 (USD MILLION)
TABLE 47 ASIA PACIFIC: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 LATIN AMERICA: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 MIDDLE EAST: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 GCC COUNTRIES: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 52 SCREENING ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: SCREENING ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: SCREENING ASSAY KITS MARKET, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: SCREENING ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 LATIN AMERICA: SCREENING ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 MIDDLE EAST: SCREENING ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 GCC COUNTRIES: SCREENING ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 SCREENING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 60 CELL-BASED ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 EUROPE: CELL-BASED ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 63 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 CELL-BASED ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 68 CELL VIABILITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 EUROPE: CELL VIABILITY ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 MIDDLE EAST: CELL VIABILITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 GCC COUNTRIES: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 CYTOTOXICITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 NORTH AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 EUROPE: CYTOTOXICITY ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 78 ASIA PACIFIC: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 LATIN AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 MIDDLE EAST: CYTOTOXICITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 GCC COUNTRIES: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 REPORTER GENE ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 83 NORTH AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 EUROPE: REPORTER GENE ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 85 ASIA PACIFIC: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 LATIN AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 MIDDLE EAST: REPORTER GENE ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 88 GCC COUNTRIES: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 OTHER CELL-BASED ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 NORTH AMERICA: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 EUROPE: OTHER CELL-BASED ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 92 ASIA PACIFIC: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 LATIN AMERICA: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 MIDDLE EAST: OTHER CELL-BASED ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 GCC COUNTRIES: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 NORTH AMERICA: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 EUROPE: BIOCHEMICAL ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 99 ASIA PACIFIC: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 LATIN AMERICA: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 MIDDLE EAST: BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 GCC COUNTRIES: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 BIOCHEMICAL ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 104 ENZYME ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 NORTH AMERICA: ENZYME ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 EUROPE: ENZYME ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 107 ASIA PACIFIC: ENZYME ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 LATIN AMERICA: ENZYME ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 MIDDLE EAST: ENZYME ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 GCC COUNTRIES: ENZYME ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 KINASE ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA: KINASE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: KINASE ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC: KINASE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 LATIN AMERICA: KINASE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 MIDDLE EAST: KINASE ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 GCC COUNTRIES: KINASE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 BINDING ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 NORTH AMERICA: BINDING ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 EUROPE: BINDING ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 121 ASIA PACIFIC: BINDING ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 LATIN AMERICA: BINDING ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 MIDDLE EAST: BINDING ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 124 GCC COUNTRIES: BINDING ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 OTHER BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 EUROPE: OTHER BIOCHEMICAL ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 128 ASIA PACIFIC: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 LATIN AMERICA: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 MIDDLE EAST: OTHER BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 131 GCC COUNTRIES: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 OTHER ASSAYS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: OTHER ASSAYS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 EUROPE: OTHER ASSAYS & KITS MARKET, 2024–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: OTHER ASSAYS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: OTHER ASSAYS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 MIDDLE EAST: OTHER ASSAYS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 GCC COUNTRIES: OTHER ASSAYS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 EUROPE: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, 2024–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 LATIN AMERICA: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 MIDDLE EAST: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 145 GCC COUNTRIES: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 COMPOUND LIBRARIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 NORTH AMERICA: COMPOUND LIBRARIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 EUROPE: COMPOUND LIBRARIES MARKET, 2024–2031 (USD MILLION)
TABLE 149 ASIA PACIFIC: COMPOUND LIBRARIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 LATIN AMERICA: COMPOUND LIBRARIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 MIDDLE EAST: COMPOUND LIBRARIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 152 GCC COUNTRIES: COMPOUND LIBRARIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 DETECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 154 NORTH AMERICA: DETECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 EUROPE: DETECTION REAGENTS MARKET, 2024–2031 (USD MILLION)
TABLE 156 ASIA PACIFIC: DETECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 LATIN AMERICA: DETECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 MIDDLE EAST: DETECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 GCC COUNTRIES: DETECTION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION)
TABLE 160 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 161 NORTH AMERICA: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 EUROPE: 3D CELL CULTURE PRODUCTS MARKET, 2024–2031 (USD MILLION)
TABLE 163 ASIA PACIFIC: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 LATIN AMERICA: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 MIDDLE EAST: 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 GCC COUNTRIES: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 3D CELL CULTURE PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 169 NORTH AMERICA: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 EUROPE: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, 2024–2031 (USD MILLION)
TABLE 171 ASIA PACIFIC: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 LATIN AMERICA: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 MIDDLE EAST: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 GCC COUNTRIES: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 176 NORTH AMERICA: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 EUROPE: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, 2024–2031 (USD MILLION)
TABLE 178 ASIA PACIFIC: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 LATIN AMERICA: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 MIDDLE EAST: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 181 GCC COUNTRIES: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 OTHER 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 NORTH AMERICA: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 EUROPE: OTHER 3D CELL CULTURE PRODUCTS MARKET, 2024–2031 (USD MILLION)
TABLE 185 ASIA PACIFIC: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 LATIN AMERICA: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 MIDDLE EAST: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 188 GCC COUNTRIES: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 OTHER HTS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 190 NORTH AMERICA: OTHER HTS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 EUROPE: OTHER HTS CONSUMABLES MARKET, 2024–2031 (USD MILLION)
TABLE 192 ASIA PACIFIC: OTHER HTS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 LATIN AMERICA: OTHER HTS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 MIDDLE EAST: OTHER HTS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 195 GCC COUNTRIES: OTHER HTS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 HTS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 197 NORTH AMERICA: HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 EUROPE: HTS INSTRUMENTS MARKET, 2024–2031 (USD MILLION)
TABLE 199 ASIA PACIFIC: HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 LATIN AMERICA: HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 MIDDLE EAST: HTS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 202 GCC COUNTRIES: HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 HTS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 204 DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 205 NORTH AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 EUROPE: DETECTION & IMAGING SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 207 ASIA PACIFIC: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 LATIN AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 MIDDLE EAST: DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 210 GCC COUNTRIES: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 DETECTION & IMAGING SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 MICROPLATE READERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 213 NORTH AMERICA: MICROPLATE READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 EUROPE: MICROPLATE READERS MARKET, 2024–2031 (USD MILLION)
TABLE 215 ASIA PACIFIC: MICROPLATE READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 LATIN AMERICA: MICROPLATE READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 MIDDLE EAST: MICROPLATE READERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 218 GCC COUNTRIES: MICROPLATE READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 220 NORTH AMERICA: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221 EUROPE: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 222 ASIA PACIFIC: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 LATIN AMERICA: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 MIDDLE EAST: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 225 GCC COUNTRIES: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 CELL ANALYSIS SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 227 NORTH AMERICA: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 EUROPE: CELL ANALYSIS SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 229 ASIA PACIFIC: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 LATIN AMERICA: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 MIDDLE EAST: CELL ANALYSIS SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 232 GCC COUNTRIES: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 LABEL-FREE DETECTION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 234 NORTH AMERICA: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 EUROPE: LABEL-FREE DETECTION SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 236 ASIA PACIFIC: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 LATIN AMERICA: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 MIDDLE EAST: LABEL-FREE DETECTION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 239 GCC COUNTRIES: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 241 NORTH AMERICA: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 EUROPE: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 243 ASIA PACIFIC: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 LATIN AMERICA: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 MIDDLE EAST: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 246 GCC COUNTRIES: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 248 NORTH AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 EUROPE: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 250 ASIA PACIFIC: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 LATIN AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 MIDDLE EAST: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 253 GCC COUNTRIES: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 255 NORTH AMERICA: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 EUROPE: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 257 ASIA PACIFIC: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 LATIN AMERICA: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 MIDDLE EAST: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 260 GCC COUNTRIES: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 OTHER HTS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 262 NORTH AMERICA: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 EUROPE: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 ASIA PACIFIC: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 LATIN AMERICA: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266 MIDDLE EAST: OTHER HTS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 267 GCC COUNTRIES: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 HTS SOFTWARE & INFORMATICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 269 NORTH AMERICA: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 EUROPE: HTS SOFTWARE & INFORMATICS MARKET, 2024–2031 (USD MILLION)
TABLE 271 ASIA PACIFIC: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 LATIN AMERICA: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 MIDDLE EAST: HTS SOFTWARE & INFORMATICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 274 GCC COUNTRIES: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 276 CELL-BASED SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 277 NORTH AMERICA: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 EUROPE: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 ASIA PACIFIC: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280 LATIN AMERICA: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 MIDDLE EAST: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 282 GCC COUNTRIES: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 284 NORTH AMERICA: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 EUROPE: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 ASIA PACIFIC: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287 LATIN AMERICA: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 MIDDLE EAST: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 289 GCC COUNTRIES: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 291 NORTH AMERICA: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 EUROPE: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 ASIA PACIFIC: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294 LATIN AMERICA: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 MIDDLE EAST: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 296 GCC COUNTRIES: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 298 NORTH AMERICA: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 EUROPE: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 ASIA PACIFIC: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301 LATIN AMERICA: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302 MIDDLE EAST: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 303 GCC COUNTRIES: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 305 NORTH AMERICA: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 EUROPE: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 ASIA PACIFIC: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 308 LATIN AMERICA: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309 MIDDLE EAST: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 310 GCC COUNTRIES: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 311 LABEL-FREE SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 1 HIGH-THROUGHPUT SCREENING (HTS) MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 HIGH-THROUGHPUT SCREENING (HTS) MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 HIGH-THROUGHPUT SCREENING (HTS) MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 4 HIGH-THROUGHPUT SCREENING (HTS) MARKET: ROLE IN ECOSYSTEM
TABLE 5 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 6 AVERAGE SELLING PRICE TREND OF HTS PRODUCTS, BY REGION, 2023–2025 (USD)
TABLE 7 IMPORT VALUE FOR HS CODE 902730, 2021–2025 (USD THOUSAND)
TABLE 8 IMPORT VOLUME FOR HS CODE 902730, 2021–2025 (TONS)
TABLE 9 IMPORT VALUE FOR HS CODE 902781, 2022–2025 (USD THOUSAND)
TABLE 10 IMPORT VOLUME FOR HS CODE 902781, 2022–2025 (UNITS)
TABLE 11 EXPORT VALUE FOR HS CODE 902730, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 12 EXPORT VOLUME FOR HS CODE 902730, BY COUNTRY, 2021–2025 (TONS)
TABLE 13 EXPORT VALUE FOR HS CODE 902781, 2022–2025 (USD THOUSAND)
TABLE 14 EXPORT VOLUME FOR HS CODE 902781, 2022–2025 (UNITS)
TABLE 15 HIGH-THROUGHPUT SCREENING (HTS) MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 17 HIGH-THROUGHPUT SCREENING (HTS) MARKET: INDICATIVE LIST OF PATENTS, 2026
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
TABLE 19 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN HIGH-THROUGHPUT SCREENING
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 US FOOD AND DRUG ADMINISTRATION: MEDICAL DEVICE CLASSIFICATION
TABLE 25 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
TABLE 27 KEY BUYING CRITERIA, BY END USER
TABLE 28 HIGH-THROUGHPUT SCREENING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 29 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 EUROPE: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 LATIN AMERICA: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 MIDDLE EAST: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 GCC COUNTRIES: HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 NORTH AMERICA: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 EUROPE: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 LATIN AMERICA: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 MIDDLE EAST: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 GCC COUNTRIES: HIGH-THROUGHPUT SCREENING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 44 HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 NORTH AMERICA: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 EUROPE: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, 2024–2031 (USD MILLION)
TABLE 47 ASIA PACIFIC: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 LATIN AMERICA: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 MIDDLE EAST: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 GCC COUNTRIES: HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 HTS REAGENTS, KITS, AND CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 52 SCREENING ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: SCREENING ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: SCREENING ASSAY KITS MARKET, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: SCREENING ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 LATIN AMERICA: SCREENING ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 MIDDLE EAST: SCREENING ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 GCC COUNTRIES: SCREENING ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 SCREENING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 60 CELL-BASED ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 EUROPE: CELL-BASED ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 63 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 CELL-BASED ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 68 CELL VIABILITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 EUROPE: CELL VIABILITY ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 MIDDLE EAST: CELL VIABILITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 GCC COUNTRIES: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 CYTOTOXICITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 NORTH AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 EUROPE: CYTOTOXICITY ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 78 ASIA PACIFIC: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 LATIN AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 MIDDLE EAST: CYTOTOXICITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 GCC COUNTRIES: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 REPORTER GENE ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 83 NORTH AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 EUROPE: REPORTER GENE ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 85 ASIA PACIFIC: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 LATIN AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 MIDDLE EAST: REPORTER GENE ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 88 GCC COUNTRIES: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 OTHER CELL-BASED ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 NORTH AMERICA: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 EUROPE: OTHER CELL-BASED ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 92 ASIA PACIFIC: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 LATIN AMERICA: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 MIDDLE EAST: OTHER CELL-BASED ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 GCC COUNTRIES: OTHER CELL-BASED ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 NORTH AMERICA: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 EUROPE: BIOCHEMICAL ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 99 ASIA PACIFIC: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 LATIN AMERICA: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 MIDDLE EAST: BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 GCC COUNTRIES: BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 BIOCHEMICAL ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 104 ENZYME ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 NORTH AMERICA: ENZYME ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 EUROPE: ENZYME ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 107 ASIA PACIFIC: ENZYME ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 LATIN AMERICA: ENZYME ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 MIDDLE EAST: ENZYME ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 GCC COUNTRIES: ENZYME ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 KINASE ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 NORTH AMERICA: KINASE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 EUROPE: KINASE ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 114 ASIA PACIFIC: KINASE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 LATIN AMERICA: KINASE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 MIDDLE EAST: KINASE ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 GCC COUNTRIES: KINASE ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 BINDING ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 NORTH AMERICA: BINDING ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 EUROPE: BINDING ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 121 ASIA PACIFIC: BINDING ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 LATIN AMERICA: BINDING ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 MIDDLE EAST: BINDING ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 124 GCC COUNTRIES: BINDING ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 OTHER BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 EUROPE: OTHER BIOCHEMICAL ASSAYS MARKET, 2024–2031 (USD MILLION)
TABLE 128 ASIA PACIFIC: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 LATIN AMERICA: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 MIDDLE EAST: OTHER BIOCHEMICAL ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 131 GCC COUNTRIES: OTHER BIOCHEMICAL ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 OTHER ASSAYS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: OTHER ASSAYS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 EUROPE: OTHER ASSAYS & KITS MARKET, 2024–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: OTHER ASSAYS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: OTHER ASSAYS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 MIDDLE EAST: OTHER ASSAYS & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 GCC COUNTRIES: OTHER ASSAYS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 EUROPE: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, 2024–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 LATIN AMERICA: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 MIDDLE EAST: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 145 GCC COUNTRIES: BIOLOGICAL & CELL CULTURE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 COMPOUND LIBRARIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 NORTH AMERICA: COMPOUND LIBRARIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 EUROPE: COMPOUND LIBRARIES MARKET, 2024–2031 (USD MILLION)
TABLE 149 ASIA PACIFIC: COMPOUND LIBRARIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 LATIN AMERICA: COMPOUND LIBRARIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 MIDDLE EAST: COMPOUND LIBRARIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 152 GCC COUNTRIES: COMPOUND LIBRARIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 DETECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 154 NORTH AMERICA: DETECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 EUROPE: DETECTION REAGENTS MARKET, 2024–2031 (USD MILLION)
TABLE 156 ASIA PACIFIC: DETECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 LATIN AMERICA: DETECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 MIDDLE EAST: DETECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 GCC COUNTRIES: DETECTION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION)
TABLE 160 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 161 NORTH AMERICA: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 EUROPE: 3D CELL CULTURE PRODUCTS MARKET, 2024–2031 (USD MILLION)
TABLE 163 ASIA PACIFIC: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 LATIN AMERICA: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 MIDDLE EAST: 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 GCC COUNTRIES: 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 3D CELL CULTURE PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 169 NORTH AMERICA: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 EUROPE: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, 2024–2031 (USD MILLION)
TABLE 171 ASIA PACIFIC: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 LATIN AMERICA: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 MIDDLE EAST: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 GCC COUNTRIES: SCAFFOLD-BASED 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 176 NORTH AMERICA: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 EUROPE: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, 2024–2031 (USD MILLION)
TABLE 178 ASIA PACIFIC: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 LATIN AMERICA: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 MIDDLE EAST: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 181 GCC COUNTRIES: SCAFFOLD-FREE 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 OTHER 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 183 NORTH AMERICA: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 EUROPE: OTHER 3D CELL CULTURE PRODUCTS MARKET, 2024–2031 (USD MILLION)
TABLE 185 ASIA PACIFIC: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 LATIN AMERICA: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 MIDDLE EAST: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 188 GCC COUNTRIES: OTHER 3D CELL CULTURE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 OTHER HTS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 190 NORTH AMERICA: OTHER HTS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 EUROPE: OTHER HTS CONSUMABLES MARKET, 2024–2031 (USD MILLION)
TABLE 192 ASIA PACIFIC: OTHER HTS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 LATIN AMERICA: OTHER HTS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 MIDDLE EAST: OTHER HTS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 195 GCC COUNTRIES: OTHER HTS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 HTS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 197 NORTH AMERICA: HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 EUROPE: HTS INSTRUMENTS MARKET, 2024–2031 (USD MILLION)
TABLE 199 ASIA PACIFIC: HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 LATIN AMERICA: HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 MIDDLE EAST: HTS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 202 GCC COUNTRIES: HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 HTS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 204 DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 205 NORTH AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 EUROPE: DETECTION & IMAGING SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 207 ASIA PACIFIC: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 LATIN AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 MIDDLE EAST: DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 210 GCC COUNTRIES: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 DETECTION & IMAGING SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 MICROPLATE READERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 213 NORTH AMERICA: MICROPLATE READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 EUROPE: MICROPLATE READERS MARKET, 2024–2031 (USD MILLION)
TABLE 215 ASIA PACIFIC: MICROPLATE READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 LATIN AMERICA: MICROPLATE READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 MIDDLE EAST: MICROPLATE READERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 218 GCC COUNTRIES: MICROPLATE READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 220 NORTH AMERICA: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221 EUROPE: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 222 ASIA PACIFIC: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 LATIN AMERICA: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 MIDDLE EAST: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 225 GCC COUNTRIES: HIGH-CONTENT SCREENING & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 CELL ANALYSIS SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 227 NORTH AMERICA: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 EUROPE: CELL ANALYSIS SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 229 ASIA PACIFIC: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 LATIN AMERICA: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 MIDDLE EAST: CELL ANALYSIS SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 232 GCC COUNTRIES: CELL ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 LABEL-FREE DETECTION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 234 NORTH AMERICA: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 EUROPE: LABEL-FREE DETECTION SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 236 ASIA PACIFIC: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 LATIN AMERICA: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 MIDDLE EAST: LABEL-FREE DETECTION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 239 GCC COUNTRIES: LABEL-FREE DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 241 NORTH AMERICA: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 EUROPE: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 243 ASIA PACIFIC: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 LATIN AMERICA: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 MIDDLE EAST: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 246 GCC COUNTRIES: MICROFLUIDIC & MINIATURIZED SCREENING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 248 NORTH AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 EUROPE: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 250 ASIA PACIFIC: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 LATIN AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 MIDDLE EAST: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 253 GCC COUNTRIES: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 255 NORTH AMERICA: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 EUROPE: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, 2024–2031 (USD MILLION)
TABLE 257 ASIA PACIFIC: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 LATIN AMERICA: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 MIDDLE EAST: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 260 GCC COUNTRIES: ROBOTIC HTS PLATFORMS & AUTOMATED WORKFLOW SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261 OTHER HTS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 262 NORTH AMERICA: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 EUROPE: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 ASIA PACIFIC: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 LATIN AMERICA: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266 MIDDLE EAST: OTHER HTS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 267 GCC COUNTRIES: OTHER HTS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268 HTS SOFTWARE & INFORMATICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 269 NORTH AMERICA: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 EUROPE: HTS SOFTWARE & INFORMATICS MARKET, 2024–2031 (USD MILLION)
TABLE 271 ASIA PACIFIC: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 LATIN AMERICA: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 MIDDLE EAST: HTS SOFTWARE & INFORMATICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 274 GCC COUNTRIES: HTS SOFTWARE & INFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 HIGH-THROUGHPUT SCREENING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 276 CELL-BASED SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 277 NORTH AMERICA: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278 EUROPE: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 ASIA PACIFIC: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280 LATIN AMERICA: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 MIDDLE EAST: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 282 GCC COUNTRIES: CELL-BASED SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 284 NORTH AMERICA: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285 EUROPE: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286 ASIA PACIFIC: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287 LATIN AMERICA: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288 MIDDLE EAST: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 289 GCC COUNTRIES: ULTRA-HIGH-THROUGHPUT & AUTOMATION TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290 HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 291 NORTH AMERICA: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292 EUROPE: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293 ASIA PACIFIC: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294 LATIN AMERICA: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295 MIDDLE EAST: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 296 GCC COUNTRIES: HIGH-CONTENT SCREENING (HCS) TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297 BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 298 NORTH AMERICA: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299 EUROPE: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300 ASIA PACIFIC: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301 LATIN AMERICA: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302 MIDDLE EAST: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 303 GCC COUNTRIES: BIOCHEMICAL SCREENING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 305 NORTH AMERICA: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306 EUROPE: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307 ASIA PACIFIC: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 308 LATIN AMERICA: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309 MIDDLE EAST: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 310 GCC COUNTRIES: 3D CELL CULTURE & ADVANCED CELLULAR MODEL TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 311 LABEL-FREE SCREENING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 HTS MARKET SEGMENTATION
FIGURE 2 REGIONS CONSIDERED
FIGURE 3 HIGH-THROUGHPUT SCREENING MARKET: YEARS CONSIDERED
FIGURE 4 MARKET SCENARIO
FIGURE 5 GLOBAL HIGH-THROUGHPUT SCREENING MARKET, 2024–2031
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HIGH-THROUGHPUT SCREENING MARKET, 2023–2026
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF HIGH-THROUGHPUT SCREENING MARKET
FIGURE 8 HIGH-GROWTH SEGMENTS IN HIGH-THROUGHPUT SCREENING MARKET, 2026–2031
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HIGH-THROUGHPUT SCREENING MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 10 GROWING ADOPTION OF OPEN INNOVATIVE MODELS TO DRIVE MARKET GROWTH
FIGURE 11 US AND REAGENTS, KITS, AND CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF HIGH-THROUGHPUT SCREENING MARKET IN NORTH AMERICA IN 2025
FIGURE 12 ASIA PACIFIC LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL HIGH-THROUGHPUT SCREENING MARKET DURING FORECAST PERIOD
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 14 HIGH-THROUGHPUT SCREENING (HTS) MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15 HIGH-THROUGHPUT SCREENING (HTS) MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16 GLOBAL GDP GROWTH (2020–2030)
FIGURE 17 HIGH-THROUGHPUT SCREENING (HTS) MARKET: VALUE CHAIN ANALYSIS
FIGURE 18 HIGH-THROUGHPUT SCREENING (HTS) MARKET ECOSYSTEM
FIGURE 19 AVERAGE SELLING PRICE TREND OF LIQUID HANDLING SYSTEMS, BY KEY PLAYER, 2023–2025 (USD)
FIGURE 20 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
FIGURE 21 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR HIGH-THROUGHPUT SCREENING PATENTS, 2015–2025
FIGURE 23 IMPACT OF AI/GEN AI ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
FIGURE 25 KEY BUYING CRITERIA, BY END USER
FIGURE 26 FLOW CYTOMETRY INSTRUMENTS (CELL ANALYZERS) MARKET, 2024–2031 (UNITS)
FIGURE 27 NORTH AMERICA: HIGH-THROUGHPUT SCREENING MARKET SNAPSHOT
FIGURE 28 ASIA PACIFIC: HIGHT-THROUGHPUT SCREENING MARKET SNAPSHOT
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 31 HIGH-THROUGHPUT SCREENING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 32 HIGH-THROUGHPUT SCREENING MARKET: COMPANY FOOTPRINT
FIGURE 33 HIGH-THROUGHPUT SCREENING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 34 EV/EBITDA OF KEY VENDORS
FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 36 HIGH-THROUGHPUT SCREENING MARKET: BRAND/PRODUCT/SERVICE COMPARATIVE ANALYSIS
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 41 REVVITY, INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 TECAN GROUP LTD.: COMPANY SNAPSHOT (2025)
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2025)
FIGURE 45 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY SNAPSHOT (2025)
FIGURE 46 LONZA GROUP: COMPANY SNAPSHOT (2025)
FIGURE 47 WATERS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 48 SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 49 EPPENDORF SE: COMPANY SNAPSHOT (2024)
FIGURE 50 PORVAIR PLC: COMPANY SNAPSHOT (2025)
FIGURE 51 GREINER AG: COMPANY SNAPSHOT (2025)
FIGURE 52 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2025)
FIGURE 53 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 54 HIGHT-THROUGHPUT SCREENING MARKET: RESEARCH DESIGN
FIGURE 55 HIGHT-THROUGHPUT SCREENING MARKET: BREAKDOWN OF PRIMARIES
FIGURE 56 GLOBAL HIGH-THROUGHPUT SCREENING MARKET ESTIMATION, 2025
FIGURE 57 HIGH-THROUGHPUT SCREENING MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
FIGURE 58 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE ANALYSIS (2025)
FIGURE 59 HIGH-THROUGHPUT SCREENING MARKET: INSIGHTS FROM PRIMARIES
FIGURE 60 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 61 HIGH-THROUGHPUT SCREENING MARKET: CAGR PROJECTIONS
FIGURE 62 HTS MARKET: DATA TRIANGULATION
FIGURE 1 HTS MARKET SEGMENTATION
FIGURE 2 REGIONS CONSIDERED
FIGURE 3 HIGH-THROUGHPUT SCREENING MARKET: YEARS CONSIDERED
FIGURE 4 MARKET SCENARIO
FIGURE 5 GLOBAL HIGH-THROUGHPUT SCREENING MARKET, 2024–2031
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HIGH-THROUGHPUT SCREENING MARKET, 2023–2026
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF HIGH-THROUGHPUT SCREENING MARKET
FIGURE 8 HIGH-GROWTH SEGMENTS IN HIGH-THROUGHPUT SCREENING MARKET, 2026–2031
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HIGH-THROUGHPUT SCREENING MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 10 GROWING ADOPTION OF OPEN INNOVATIVE MODELS TO DRIVE MARKET GROWTH
FIGURE 11 US AND REAGENTS, KITS, AND CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF HIGH-THROUGHPUT SCREENING MARKET IN NORTH AMERICA IN 2025
FIGURE 12 ASIA PACIFIC LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL HIGH-THROUGHPUT SCREENING MARKET DURING FORECAST PERIOD
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 14 HIGH-THROUGHPUT SCREENING (HTS) MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15 HIGH-THROUGHPUT SCREENING (HTS) MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16 GLOBAL GDP GROWTH (2020–2030)
FIGURE 17 HIGH-THROUGHPUT SCREENING (HTS) MARKET: VALUE CHAIN ANALYSIS
FIGURE 18 HIGH-THROUGHPUT SCREENING (HTS) MARKET ECOSYSTEM
FIGURE 19 AVERAGE SELLING PRICE TREND OF LIQUID HANDLING SYSTEMS, BY KEY PLAYER, 2023–2025 (USD)
FIGURE 20 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
FIGURE 21 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR HIGH-THROUGHPUT SCREENING PATENTS, 2015–2025
FIGURE 23 IMPACT OF AI/GEN AI ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
FIGURE 25 KEY BUYING CRITERIA, BY END USER
FIGURE 26 FLOW CYTOMETRY INSTRUMENTS (CELL ANALYZERS) MARKET, 2024–2031 (UNITS)
FIGURE 27 NORTH AMERICA: HIGH-THROUGHPUT SCREENING MARKET SNAPSHOT
FIGURE 28 ASIA PACIFIC: HIGHT-THROUGHPUT SCREENING MARKET SNAPSHOT
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 31 HIGH-THROUGHPUT SCREENING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 32 HIGH-THROUGHPUT SCREENING MARKET: COMPANY FOOTPRINT
FIGURE 33 HIGH-THROUGHPUT SCREENING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 34 EV/EBITDA OF KEY VENDORS
FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 36 HIGH-THROUGHPUT SCREENING MARKET: BRAND/PRODUCT/SERVICE COMPARATIVE ANALYSIS
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 41 REVVITY, INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 TECAN GROUP LTD.: COMPANY SNAPSHOT (2025)
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2025)
FIGURE 45 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY SNAPSHOT (2025)
FIGURE 46 LONZA GROUP: COMPANY SNAPSHOT (2025)
FIGURE 47 WATERS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 48 SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 49 EPPENDORF SE: COMPANY SNAPSHOT (2024)
FIGURE 50 PORVAIR PLC: COMPANY SNAPSHOT (2025)
FIGURE 51 GREINER AG: COMPANY SNAPSHOT (2025)
FIGURE 52 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2025)
FIGURE 53 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 54 HIGHT-THROUGHPUT SCREENING MARKET: RESEARCH DESIGN
FIGURE 55 HIGHT-THROUGHPUT SCREENING MARKET: BREAKDOWN OF PRIMARIES
FIGURE 56 GLOBAL HIGH-THROUGHPUT SCREENING MARKET ESTIMATION, 2025
FIGURE 57 HIGH-THROUGHPUT SCREENING MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
FIGURE 58 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE ANALYSIS (2025)
FIGURE 59 HIGH-THROUGHPUT SCREENING MARKET: INSIGHTS FROM PRIMARIES
FIGURE 60 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 61 HIGH-THROUGHPUT SCREENING MARKET: CAGR PROJECTIONS
FIGURE 62 HTS MARKET: DATA TRIANGULATION
